CanSino Biologics (SEHK:6185) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

6185 주식 개요

는 중화인민공화국에서 백신을 개발, 제조 및 상용화하는 회사입니다.

6185 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	5/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 89.9% 에서 거래

수익은 매년 124.55% 증가할 것으로 예상됩니다.

위험 분석

위험 검사에서 6185 에 대한 위험이 감지되지 않았습니다.

CanSino Biologics Inc. 경쟁사

AIM Vaccine

SEHK:6660

HK$8.6b

Shanghai Junshi Biosciences

SEHK:1877

HK$26.1b

InnoCare Pharma

SEHK:9969

HK$8.9b

3SBio

SEHK:1530

HK$14.5b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 CanSino Biologics
과거 주가
현재 주가	HK$20.00
52주 최고치	HK$33.20
52주 최저치	HK$14.80
베타	0.53
11개월 변경	-2.68%
3개월 변경 사항	23.00%
1년 변경 사항	-22.93%
33년 변화	-95.25%
5년 변화	-41.35%
IPO 이후 변화	-42.36%

최근 뉴스 및 업데이트

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11

Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?

Dec 26

CanSino Biologics (HKG:6185) Seems To Use Debt Quite Sensibly

Oct 01

CanSino Biologics' (HKG:6185) Earnings Aren't As Good As They Appear

Sep 05

주주 수익률

	6185	HK Biotechs	HK 마켓
7D	-11.7%	-1.1%	1.9%
1Y	-22.9%	-35.3%	2.1%

수익률 대 산업: 6185 지난 1년 동안 -34.3 %를 반환한 Hong Kong Biotechs 산업을 초과했습니다.

수익률 대 시장: 6185 지난 1년 동안 2.1 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is 6185's price volatile compared to industry and market?
6185 volatility
6185 Average Weekly Movement	10.1%
Biotechs Industry Average Movement	8.9%
Market Average Movement	7.2%
10% most volatile stocks in HK Market	15.4%
10% least volatile stocks in HK Market	3.7%

안정적인 주가: 6185 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: 6185 의 주간 변동성( 10% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2009	1,494	Xuefeng Yu	www.cansinotech.com

는 중화인민공화국에서 백신을 개발, 제조 및 상용화하는 회사입니다. 이 회사는 컨비데시아와 재조합 신종 코로나바이러스 감염증에 대한 흡입용 백신인 Ad5-nCoV, 에볼라 바이러스 백신인 Ad5-EBOV, 수막구균 예방을 위한 MCV2 및 MCV4 백신을 개발합니다. 1차 백신 접종 후 백일해 예방 효과가 약해지는 문제를 해결하기 위해 영아용 DTcP 백신과 DTcP 부스터 백신을 개발해 임상 1상 시험을 진행 중입니다.

CanSino Biologics Inc. 기본 사항 요약

CanSino Biologics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
6185 기본 통계
시가총액	HK$8.00b
수익(TTM)	-HK$1.63b
수익(TTM)	HK$398.60m

12.4x

P/S 비율

-3.0x

P/E 비율

6185 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
6185 손익 계산서(TTM)
수익	CN¥370.81m
수익 비용	CN¥781.88m
총 이익	-CN¥411.06m
기타 비용	CN¥1.10b
수익	-CN¥1.51b

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-6.13
총 마진	-110.85%
순이익 마진	-408.10%
부채/자본 비율	47.5%

6185 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

6185 주식 개요

보상

위험 분석

CanSino Biologics Inc. 경쟁사

SEHK:6660

HK$8.6b

SEHK:1877

HK$26.1b

SEHK:9969

HK$8.9b

SEHK:1530

HK$14.5b

가격 내역 및 성능

최근 뉴스 및 업데이트

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Consensus EPS estimates fall by 73%

Consensus revenue estimates fall by 12%

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Consensus revenue estimates fall by 41%

Investor sentiment deteriorated over the past week

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Second quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥3.67 profit in 2Q 2021)

CanSino Biologics Inc. to Report Q2, 2022 Results on Aug 26, 2022